## Immuno- and serological evaluation of neurodegeneration after spinal cord injury (SCI) and the potential impact of high oxygen therapy

David D Fuller<sup>1,2,3</sup> Anna F Fusco<sup>2, 3</sup>, Kyle Deegan<sup>3</sup>, Gabriel Igelesias<sup>1,3</sup>, Sabhya Rana<sup>1,2,3</sup>, Sruti Rayaprolu<sup>4</sup>, Maya M MacIntyre<sup>3</sup>, Marda Jorgensen<sup>5</sup>, Gerry Shaw<sup>2,5,6</sup>

Several epitopes on the neurofilament light chain (NF-L) are exposed by degeneration induced proteolysis and are specifically recognized by Degenotag™ type antibodies, novel reagents for visualizing neurodegeneration (PMID 37091583). We used a rat cervical (C4) contusion SCI model to compare the time course of NF-L release into serum (Quanterix<sup>®</sup> Simoa™ NF-L assay) with spinal cord staining quantified with the NF-L Degenotag™ MCA-6H63 antibody (RRID Ab 2923484). Spinal cords and serum were collected at intervals from 1 hr - 10 days post-SCI. Serum NF-L and spinal MCA-6H63 staining peaked at 1-3 days. Serum NF-L values correlated with the number of MCA-6H63 positive axons (R<sup>2</sup>=0.739; p<0.0001). We also examined the impact of hyperoxia on the injured spinal cord. We previously demonstrated that hyperbaric oxygen delivered at acute (min-hrs) through sub-acute (days) times after SCI can partially mitigate neuronal loss (PMID: 35152735). Subsequent work suggested that normobaric oxygen may have similar impact (PMID: 38110993). Thus, adult rats were treated with normobaric hyperoxia (100% O<sub>2</sub>, 2 hours) within 20 min of C4 contusion and daily for 7 days. Cords were harvested on day 14 and analyzed ± 2 mm from the lesion epicenter by staining with an antibody to neuronal nuclear protein (NeuN). Hyperoxia treated rats (n=3) had an approximately 30% increase in neuronal Ongoing work will examine MCA-6H63 staining after hyperoxia counts vs. sham (n=3). treatments. This work demonstrates the utility of serum NF-L as a biomarker axonal degeneration and suggests that normobaric hyperoxia treatments in the acute through sub-acute period may provide benefit.

**Sponsored By**: 1R01NS139422-01 (DDF); 1K99NS133388-01A (SR), 5T32HD043730-19 (DDF: PI; AFF: trainee), Frank M Davis Chairman Emeritus Grant (AFF)

## **Presenter Name and contact information:**

David Fuller, Ph.D., Professor Department of Physical Therapy University of Florida Gainesville, Florida, USA Email: dfuller@phhp.ufl.edu

<sup>&</sup>lt;sup>1</sup>Physical Therapy Department, University of Florida

<sup>&</sup>lt;sup>2</sup>McKnight Brain Institute, University of Florida

<sup>&</sup>lt;sup>3</sup>Breathing Research and Therapeutics Center, University of Florida

<sup>&</sup>lt;sup>4</sup>Center for Translational Research in Neurodegenerative Disease, University of Florida

<sup>&</sup>lt;sup>5</sup>EnCor Biotechnology Inc. Gainesville, Florida

<sup>&</sup>lt;sup>6</sup>Department of Neuroscience, University of Florida